Table 4. Patients sub grouped according to disease behaviour, L4 phenotype and surgery.
| Disease behaviour and severity | |||||||||
| overall | L1 | L2 | L3 | ileal CD | CD | controls <> L1+L3 | |||
| disease behaviour | B1 (inflammatory) | 17,12% | 67,71% | 22,20% | 20,73% | 31,31% | |||
| MAF | 26,32% | 24,17% | 28,10% | 27,67% | 25,97% | ||||
| B2 (stricturing) | 50,90% | 7,17% | 27,71% | 34,42% | 28,28% | statistics for stricturing behaviour | C<>T | CC<>CT+TT | |
| MAF | 30,97% | 21,88% | 31,46% | 31,25% | 30,71% | 1.32; p = 0.00686 | 1.34; p = 0.02745 | ||
| B3 (penetrating) | 31,98% | 25,11% | 50,09% | 44,85% | 40,40% | Armitage's trend | CC<>TT | ||
| MAF | 31,69% | 26,79% | 28,02% | 28,78% | 28,50% | 1.30; p = 0.00963 | 1.71; p = 0.01460 | ||
| upper GI involvement | L4 | 11,84% | 8,00% | 16,03% | 14,80% | 13,27% | statistics for L4 | C<>T | CC<>CT+TT |
| MAF | 35,19% | 22,22% | 31,25% | 32,17% | 30,83% | 1.38; p = 0.02882 | 1.50; p = 0.03749 | ||
| no L4 | 88,16% | 92,00% | 83,97% | 85,20% | 86,73% | Armitage's trend | CC<>TT | ||
| MAF | 29,60% | 24,88% | 29,18% | 29,31% | 28,25% | 1.33; p = 0.03561 | 1.68; p = 0.10543 | ||
| surgery | at least one | 77,97% | 33,33% | 64,68% | 68,54% | 60,68% | |||
| MAF | 30,79% | 24,00% | 29,11% | 29,66% | 28,97% | ||||
| no | 22,03% | 66,67% | 35,32% | 31,46% | 39,32% | ||||
| MAF | 29,00% | 25,00% | 29,59% | 29,47% | 27,78% | ||||
MAF = minor allele frequency.
Shown are percentages of individuals per group as well as the TCF-4 (TCF7L2) rs3814570 T- allele frequency (minor allele frequency MAF). Differences in genotype distribution compared to controls (all controls from Table 2) in general as well as the amount of all carriers (allele positivity) and the amount of homozygous carriers were subject to t- tests in patients with ileal CD. Finally, results of the Armitage's trend tests for verification of significant associations of the rare T- variant are shown.